We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Exostar’s Life Sciences Cloud Collaboration Platform Exceeds Growth Objectives
News

Exostar’s Life Sciences Cloud Collaboration Platform Exceeds Growth Objectives

Exostar’s Life Sciences Cloud Collaboration Platform Exceeds Growth Objectives
News

Exostar’s Life Sciences Cloud Collaboration Platform Exceeds Growth Objectives

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Exostar’s Life Sciences Cloud Collaboration Platform Exceeds Growth Objectives"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Exostar, whose cloud-based solutions enable secure, cost-effective business-to-business collaboration, has announced significant milestones in the adoption of its community cloud access and collaboration service offering for the Life Sciences industry.  Led by two of the ten largest global pharmaceutical companies, more than 500 organizations supporting over 10,000 individuals in 46 countries on six continents are leveraging Exostar’s Life Sciences Identity Hub and Secure Access Manager (SAM) to safely, securely, and cost-effectively collaborate in the cloud.

Exostar’s solutions are an enabler that supports the transformation of the drug research and development (R&D) process.  Rather than go it alone, companies are embracing a partner-centric R&D model that speeds time-to-market for new drugs and therapies.  Exostar’s community offering in the cloud addresses three key business tenets:

    Connect once (to access applications across enterprise boundaries)
    Collect once (to share partner attribute information with relying parties)
    Certify once (to reduce the cost of multiple audits)

The Exostar Life Sciences Identity Hub brings together organizations and their systems, applications, and information.  The cloud-based Identity Hub, delivered as-a-Service, eliminates the need for companies including manufacturers, clinical research organizations, and academic institutions to establish and maintain costly, redundant point-to-point interactions, freeing critical IT resources and budgets.

SAM provides employees of connected organizations with single sign-on access, using their existing credentials, to a growing list of more than 20 enterprise-class applications both on-premise and in the cloud.  SAM controls user access through strong authentication of identities, along with enforcement of the roles and privileges assigned and updated by system, application, and information owners.

Exostar teams with stakeholders in the community to define and refine the Life Science Identity Hub’s processes, rules, and governance terms that provide the flexibility and accountability necessary to ensure compliance with corporate, industry, and Government regulatory requirements, while protecting intellectual property and sensitive information from compromise.  The Life Sciences service offering builds on Exostar’s expertise in delivering similar capabilities to the Aerospace and Defense marketplace, where the community encompasses nearly 100,000 organizations and 300,000 users in 150 countries.

“Our solution is allowing Life Sciences organizations to more quickly establish new relationships, strengthen existing relationships, and reduce IT costs,” said Vijay Takanti, Exostar’s Vice President of Security and Collaboration Solutions.  “By reducing the time it takes these organizations to begin collaborating productively with their external partners from months to days, we are helping streamline the drug R&D process – driving new revenue streams for our customers while bringing life-altering drugs and therapies to market sooner.”

Advertisement